(S)-2-morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[3][1,4]diazepin-3-yl)-nicotinamide | 865471-21-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[3][1,4]diazepin-3-yl)-nicotinamide
• 英文别名: N-[(3S)-2,3-Dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(4-morpholinyl)-3-pyridinecarboxamide；2-morpholin-4-yl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]pyridine-3-carboxamide
• CAS: 865471-21-2
• 化学式: C₂₅H₂₃N₅O₃
• 分子量: 441.489
• InChiKey: GQWVFXBSJTYWDJ-JOCHJYFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  95.9
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-氨基-5-苯基-1,3-二氢-2H-1,4-苯并二氮杂革-2-酮 在 盐酸 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 40.67h， 生成 (S)-2-morpholin-4-yl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[3][1,4]diazepin-3-yl)-nicotinamide
  参考文献：
  名称：

  1,4-Benzodiazepines as Inhibitors of Respiratory Syncytial Virus. The Identification of a Clinical Candidate

  摘要：

  Respiratory syncytial virus (RSV) is the cause of one-fifth of all lower respiratory tract infections worldwide and is increasingly being recognized as representing a serious threat to patient groups with poorly functioning or immature immune systems. Racemic 1,4-benzodiazepines show potent anti-RSV activity in vitro. Anti-RSV evaluation of 3-position R- and S-benzodiazepine enantiomers and subsequent optimization of this series resulted in selection of a clinical candidate. Antiviral activity was found to reside mainly in the S-enantiomer, and the R-enantiomers were consistently less active against RSV. Analogues of 1,4-(S)-benzodiazepine were synthesized as part of the lead optimization program at Arrow and tested in the XTT assay. From this exercise, (S)-1-(2-fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]-diazepin-3-yl)-urea, 17b (RSV-604) was identified as a clinical candidate, exhibiting potent anti-RSV activity in the XTT assay, which was confirmed in secondary assays. Compound 17b also possessed a good pharmacokinetic profile and has now progressed into the clinic.

  DOI：

  10.1021/jm060747l

文献信息

• Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein
  申请人：Powell Kenneth

  公开号：US20070185096A1

  公开（公告）日：2007-08-09

  A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and: (a) an inhibitor of the RSV fusion protein; and (b) a benzodiazepine derivative capable of inhibiting RSV replication is found to be highly active against RSV.

  一种制药组合物，包括一种药用可接受载体或稀释剂和：(a)一种RSV融合蛋白的抑制剂；以及(b)一种苯二氮平衍生物，能够抑制RSV复制，发现对RSV具有高度活性。
• Benzodiazepines for Treating or Preventing Rsv Infection
  申请人：Dowdell Verity

  公开号：US20080139536A1

  公开（公告）日：2008-06-12

  Use of a compound which is (a) a benzodiazepine derivative of the formula (I) or an N-oxide thereof or (b) a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in treating or preventing an RSV infection wherein: —R 1 represents C 1-6 alkyl, aryl or heteroaryl; —R 2 represents hydrogen or C 1-6 alkyl; each R 3 is the same or different and represents halogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylthio, C 1-6 haloalkyl, C 1-6 haloalkoxy, amino, mono(C 1-6 alkyl)amino, di(C 1-6 alkyl)amino, vitro, cyano, —CO 2 R′, —CONR′R″, —NH—CO—R′, —S(O)R′, —S(O) 2 R′, —NH—S(O) 2 R′, —S(O)NR′R″ or —S(O) 2 NR′R″, wherein each R′ and R″ is the same or different and represents hydrogen or C 1-6 alkyl; n is from O to 3; R 4 represents hydrogen or C 1-6 alkyl; X represents —CO—, —CO—NR′—, —S(O)— or —S(O) 2 —, wherein R′ is hydrogen or a C 1 -C 6 alkyl group; and R 5 represents a heteroaryl or heterocyclyl group which is substituted by a C1C6 hydroxyalkyl group or a —(C 1 -C 4 alkyl)-X 1 —(C 1 -C 4 alkyl)-X 2 —(C 1 -C 4 alkyl} group, wherein X 1 represents -0-, —S— or —NR′—, wherein R′ represents H or a C 1 -C 4 alkyl group and X 2 represents —CO—, —SO— or —SO 2 —, or R 5 represents -A 1 -Y-A 2 , wherein: -A 1 is an aryl, heteroaryl, carbocyclyl or heterocyclyl group; 25 —Y represents a direct bond or a C 1 -C 4 alkylene, —SO 2 —, —CO—, -0-, —S— or —NR′-moiety, wherein R′ is a C 1 -C 6 alkyl group; and -A 2 is an aryl, heteroaryl, carbocyclyl or heterocyclyl group.

  使用化合物（a）式（I）的苯二氮平衍生物或其N-氧化物，或（b）其药学上可接受的盐，制备用于治疗或预防RSV感染的药物，其中：-R1代表C1-6烷基，芳基或杂环芳基；-R2代表氢或C1-6烷基；每个R3相同或不同，代表卤素，羟基，C1-6烷基，C1-6烷氧基，C1-6烷基硫基，C1-6卤代烷基，C1-6卤代烷氧基，氨基，单（C1-6烷基）氨基，二（C1-6烷基）氨基，体外，氰基，-CO2R'，-CONR'R"，-NH-CO-R'，-S（O）R'，-S（O）2R'，-NH-S（O）2R'，-S（O）NR'R"或-S（O）2NR'R"，其中每个R'和R"相同或不同，代表氢或C1-6烷基；n为0至3；R4代表氢或C1-6烷基；X代表-CO-，-CO-NR'-，-S（O）-或-S（O）2-，其中R'代表氢或C1-C6烷基；R5代表被C1C6羟基烷基或-(C1-C4烷基)-X1-(C1-C4烷基)-X2-(C1-C4烷基)基取代的杂环芳基或杂环烷基基团，其中X1代表-0-，-S-或-NR'-，其中R'代表H或C1-C4烷基，X2代表-CO-，-SO-或-SO2-，或R5代表-A1-Y-A2，其中：-A1是芳基，杂环芳基，碳环芳基或杂环烷基基团；-Y代表直接键或C1-C4烷基，-SO2-，-CO-，-0-，-S-或-NR'-基，其中R'是C1-C6烷基基团；-A2是芳基，杂环芳基，碳环芳基或杂环烷基基团。
• PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN
  申请人：Arrow Therapeutics Limited

  公开号：EP1727551B1

  公开（公告）日：2009-09-09
• 1,4-Benzodiazepines as Inhibitors of Respiratory Syncytial Virus. The Identification of a Clinical Candidate
  作者：Elisa A. Henderson、Dagmar G. Alber、Robert C. Baxter、Sian K. Bithell、Joanna Budworth、Malcolm C. Carter、Ann Chubb、G. Stuart Cockerill、Verity C. L. Dowdell、Ian J. Fraser、Robert A. Harris、Sally J. Keegan、Richard D. Kelsey、James A. Lumley、Jeremy N. Stables、Natasha Weerasekera、Lara J. Wilson、Kenneth L. Powell

  DOI：10.1021/jm060747l

  日期：2007.4.1

  Respiratory syncytial virus (RSV) is the cause of one-fifth of all lower respiratory tract infections worldwide and is increasingly being recognized as representing a serious threat to patient groups with poorly functioning or immature immune systems. Racemic 1,4-benzodiazepines show potent anti-RSV activity in vitro. Anti-RSV evaluation of 3-position R- and S-benzodiazepine enantiomers and subsequent optimization of this series resulted in selection of a clinical candidate. Antiviral activity was found to reside mainly in the S-enantiomer, and the R-enantiomers were consistently less active against RSV. Analogues of 1,4-(S)-benzodiazepine were synthesized as part of the lead optimization program at Arrow and tested in the XTT assay. From this exercise, (S)-1-(2-fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]-diazepin-3-yl)-urea, 17b (RSV-604) was identified as a clinical candidate, exhibiting potent anti-RSV activity in the XTT assay, which was confirmed in secondary assays. Compound 17b also possessed a good pharmacokinetic profile and has now progressed into the clinic.